Scientific Sessions 2024  /  New Targets and New Treatments: Advances in Lipid Therapeutics  /  Discussant: Lipoprotein a therapeutics, understanding the pipeline
Logo

American Heart Association

  175
  0

Final ID:

Discussant: Lipoprotein a therapeutics, understanding the pipeline

  • Tokgozoglu, Lale  ( HACETTEPE UNIVERSITY , Ankara , Turkey )
  • Goldberg, Anne  ( Washington Univ School of Medicine , St Louis , Missouri , United States )
    • Author Disclosures:
    Lale Tokgozoglu: DO have relevant financial relationships ; Advisor:Abbott:Active (exists now) ; Advisor:MSD:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:EliLilly:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Speaker:Ultragenyx:Active (exists now) ; Speaker:Sanofi:Active (exists now) ; Speaker:NovoNordisk:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:MSD:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Advisor:Daiichi Sankyo:Active (exists now) ; Advisor:Sanofi:Active (exists now) ; Speaker:Amarin:Active (exists now) ; Speaker:Amgen:Active (exists now) | Anne Goldberg: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:IONIS:Active (exists now) ; Consultant:NewAmsterdam:Active (exists now) ; Research Funding (PI or named investigator):Bio89:Active (exists now) ; Research Funding (PI or named investigator):Regeneron:Past (completed) ; Research Funding (PI or named investigator):NewAmsterdam:Active (exists now) ; Research Funding (PI or named investigator):Esperion:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):IONIS:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now) ; Research Funding (PI or named investigator):Amarin:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles

Nicholls Stephen, Ni Wei, Rhodes Grace, Nissen Steven, Navar Ann Marie, Michael Laura, Krege John

Discussant: CETP inhibition-is it time for a revival?

Watson Karol

More abstracts from these authors:
The ODYSSEY of Lipid Lowering: Navigating the Growing Array of Therapeutics for LDL-C Reduction

Tokgozoglu Lale

How Low and How Fast Should We Go with LDL-Cholesterol?

Ray Kausik, Lloyd-jones Donald, Tokgozoglu Lale

You have to be authorized to contact abstract author. Please, Login
Not Available